Comparison of antiplatelet potency of sarpogrelate, aspirin, and beraprost in healthy volunteers according to in-vitro closure time

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 3, 2010, Pages 262-265

  Kim, Kyung Min ^a   Kim, Hyunjung ^a   Chi, Hyun Sook ^a   Park, Jung Sik ^a   Kim, Soon Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Aspirin; Beraprost; Platelet function; Sarpogrelate

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BERAPROST; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; SARPOGRELATE; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLEEDING TIME; BLOOD CLOTTING PARAMETERS; DRUG ACTIVITY; DRUG POTENCY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; THROMBOCYTE FUNCTION;

ADULT; ASPIRIN; EPOPROSTENOL; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; SUCCINATES;

EID: 77950260592     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833700fc     Document Type: Article

References (13)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
2. Andersen K, HurlenM, Arnesen H, Seljeflot I. Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108:37-42.
3. Kokubu N, Tsuchihashi K, Yuda S, Hase M, Eguchi M, Wakabayashi T, et al. Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. Circ J 2006; 70:1451-1456.
4. Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004; 104:59-81.
5. Kim KM, Kim HW, Lee JH, Chang JW, Park JS, Kim SB. Effects of beraprost sodium, an oral prostaglandin i2 analog, on hemostatic factors and inflammation in chronic peritoneal dialysis patients. Perit Dial Int 2009; 29:178-181.
6. Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002; 62:107-133.
7. Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert UT, Hellstern P. Variables influencing platelet function analyzer-100 closure times in healthy individuals. Br J Haematol 2005; 130:759-767.
8. Cho YU, Jang S, Park CJ, Chi HS. Variables that affect platelet function analyzer-100 (PFA-100) closure times and establishment of reference intervals in Korean adults. Ann Clin Lab Sci 2008; 38:247-253.
9. Janzarik H, Remy S, Morell S, Pabst W. 'Haemostasis time', a modified bleeding time test and its comparison with the Duke and Ivy/template bleeding times. I. Normal values, application in thrombocytopenic patients and evaluation of heparin and aspirin effects. Blut 1986; 52:345-356.
10. Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke 2008; 39:1827-1833.
11. Uchiyama S, Ozaki Y, Satoh K, Kondo K, Nishimaru K. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cerebrovasc Dis 2007; 24:264-270.
12. Nakamura K, Kariyazono H,Moriyama Y, Toyohira H, Kubo H, Yotsumoto G, et al. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin. Blood Coagul Fibrinolysis 1999; 10:513-519.
13. Warot D, Berlin I, Aymard G, Ankri A, Fabry C, Besse B, et al. Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. Fundam Clin Pharmacol 2004; 14:231-236.